Sign in
Active, not recruitingPhase 2

A Study of Annual Doses of MK-1406/CD388 in Healthy Adults (MK-1406-006/CD388.SQ.2.07)

Key facts

Who runs it
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Where
Miami Lakes and Spartanburg, United StatesSee the 4 sitesAlso in 1 other country, 2 sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
400 people, planned
Started
29 Oct 2025
Expected to end
31 Jul 2027
Type of study
Interventional
Treatments tested
  • MK-1406 Injection
Record updated
20 August 2026

Who can take part

Age
18 years to 66 years
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 6 criteriaShow less

Who can take part

  • The main inclusion criteria include but are not limited to the following:
  • Be in stable health
  • Has previously completed participation in study CD388.SQ.2.05/MK-1406-004, and received a subcutaneous (SC) CD388/MK-1406 dose of either 150 mg, 300 mg or 450 mg

Who cannot take part

  • Have a contraindication to subcutaneous (SQ) injections and venipunctures (eg, bleeding disorders)
  • Has a known or suspected allergy or history of anaphylaxis or other serious adverse events (SAEs) to zanamivir (following administration of inhaled or intravenous formulations), monoclonal antibodies, or any of the components of CD388/MK-1406
  • The main exclusion criteria include but are not limited to the following:

Where in United States

Also in 1 other country, 2 sites

  • Floridian Clinical ResearchMiami Lakes, United States
  • Floridian Clinical Research (Site 0102)Miami Lakes, United States
  • Spartanburg Medical ResearchSpartanburg, United States
  • Spartanburg Medical Research (Site 0101)Spartanburg, United States

About the trial

What the trial wants to find out

The goal of this clinical study is to learn if giving repeated annual doses of MK-1406 (CD388) is safe and how the body reacts to it in healthy adults who have already received one dose without serious side effects. The study aims to determine if the body makes antibodies against MK-1406 after repeated doses, which might affect how the drug works or how safe it is, and to better understand the safety and tolerability of repeated doses. Participants will receive two doses of MK-1406 over two years and be monitored for 18 months. Researchers will check for immune responses against the drug, watch for any side effects, and measure how the drug behaves in the body over time. This study is based on the idea that people who tolerated MK-1406 well before will likely continue to tolerate it safely with repeated annual dosing, and that the risk of immune reactions will remain low.

The group in the trial

  • MK-1406Treatment being tested

    Participant will receive 450 mg dose of MK-1406 (CD388) by subcutaneous (SC) injection followed 1 year later by a repeat single 450 mg dose of MK-1406 administered by SC injection.

    Treatment: MK-1406 Injection

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Phase 2, Open-Label, Long-Term Study to Evaluate the Safety, Pharmacokinetics, and Occurrence of Anti-Drug Antibodies in Healthy Participants Following Annual Doses of CD388, a Novel Long-Acting Antiviral Conjugate
Record updated
20 August 2026